14th Jan 2014 12:36
LONDON (Alliance News) - Vectura Group PLC said Tuesday that its partner Sandoz has received marketing authorisation for its AirFluSal Forspira inhaler in Sweden.
The authorisation comes just a day after AirFluSal Forspira received marketing authorisation in Germany.
The AirFluSal inhaler is designed for the treatment of asthma and chronic obstructive pulmonary disease.
Shares in Vectura were trading down 0.2%, or 0.25 pence, at 153.50 pence Tuesday afternoon.
By Hana Stewart-Smith; [email protected]; @hanassallnews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
VEC.L